GeneReach Biotechnology Corp. develops, manufactures, and markets products for applied nucleic acid detection technology primarily in Taiwan.
Price History & Performance
|Historical stock prices|
|Current Share Price||NT$113.50|
|52 Week High||NT$104.00|
|52 Week Low||NT$201.00|
|1 Month Change||4.13%|
|3 Month Change||-12.36%|
|1 Year Change||-39.63%|
|3 Year Change||288.70%|
|5 Year Change||336.54%|
|Change since IPO||170.24%|
Recent News & Updates
Does GeneReach Biotechnology (GTSM:4171) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
|4171||TW Medical Equipment||TW Market|
Return vs Industry: 4171 underperformed the TW Medical Equipment industry which returned 10.8% over the past year.
Return vs Market: 4171 underperformed the TW Market which returned 39% over the past year.
Stable Share Price: 4171 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: 4171's weekly volatility (7%) has been stable over the past year.
About the Company
GeneReach Biotechnology Corp. develops, manufactures, and markets products for applied nucleic acid detection technology primarily in Taiwan. The company offers pathogen detection platforms, including equipment and reagents; and animal use medicines, biotechnology services, medical materials and equipment, and precision instruments. Its products are used in aquaculture, agriculture, food, companion animal, livestock, and human health industries.
GeneReach Biotechnology Fundamentals Summary
|4171 fundamental statistics|
Is 4171 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|4171 income statement (TTM)|
|Cost of Revenue||NT$240.44m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||8.92|
|Net Profit Margin||36.99%|
How did 4171 perform over the long term?See historical performance and comparison
Is GeneReach Biotechnology undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 4171 (NT$113.5) is trading below our estimate of fair value (NT$633.21)
Significantly Below Fair Value: 4171 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 4171 is good value based on its PE Ratio (12.7x) compared to the TW Medical Equipment industry average (23.3x).
PE vs Market: 4171 is good value based on its PE Ratio (12.7x) compared to the TW market (16.4x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 4171's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 4171 is overvalued based on its PB Ratio (4.5x) compared to the TW Medical Equipment industry average (2x).
How is GeneReach Biotechnology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as GeneReach Biotechnology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has GeneReach Biotechnology performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 4171 has a high level of non-cash earnings.
Growing Profit Margin: 4171's current net profit margins (37%) are higher than last year (22.3%).
Past Earnings Growth Analysis
Earnings Trend: 4171 has become profitable over the past 5 years, growing earnings by 77.7% per year.
Accelerating Growth: 4171's earnings growth over the past year (175.9%) exceeds its 5-year average (77.7% per year).
Earnings vs Industry: 4171 earnings growth over the past year (175.9%) exceeded the Medical Equipment industry 9.5%.
Return on Equity
High ROE: 4171's Return on Equity (33.3%) is considered high.
How is GeneReach Biotechnology's financial position?
Financial Position Analysis
Short Term Liabilities: 4171's short term assets (NT$968.0M) exceed its short term liabilities (NT$247.3M).
Long Term Liabilities: 4171's short term assets (NT$968.0M) exceed its long term liabilities (NT$150.3M).
Debt to Equity History and Analysis
Debt Level: 4171's debt to equity ratio (7.7%) is considered satisfactory.
Reducing Debt: 4171's debt to equity ratio has reduced from 44.1% to 7.7% over the past 5 years.
Debt Coverage: 4171's debt is well covered by operating cash flow (208.8%).
Interest Coverage: 4171's interest payments on its debt are well covered by EBIT (106.6x coverage).
What is GeneReach Biotechnology current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 4171's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 4171's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 4171's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 4171's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 4171's dividend in 3 years as they are not forecast to pay a notable one for the TW market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ms. Grace Chang, Ph D., serves as Chief Executive Officer at GeneReach Biotechnology Corp. Ms. Chang holds Ph.D. in Nutritional Science and Toxicology from UC Berkeley in the year 1993 to 1998 and B.S. in...
Experienced Management: 4171's management team is considered experienced (3.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
GeneReach Biotechnology Corp.'s employee growth, exchange listings and data sources
- Name: GeneReach Biotechnology Corp.
- Ticker: 4171
- Exchange: TPEX
- Founded: 2004
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: NT$4.607b
- Shares outstanding: 40.59m
- Website: https://www.genereach.com
- GeneReach Biotechnology Corp.
- Central Taiwan Science Park
- No.19, Keyuan 2nd Road
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/24 08:33|
|End of Day Share Price||2021/09/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.